Vertex halts VX-264 trials after missing efficacy goals but continues advancing zimislecel, a potential treatment for severe ...

Despite a $400 million impairment charge, analysts say the removal of a drug-device combo from its portfolio is not a huge ...

Vertex is ending work on one of its two clinical-stage islet cell treatments after the diabetes therapy looked unlikely to trigger sufficient levels of insulin production in a phase 1/2 trial.

Vertex holds a dominant position in the cystic ... for enhanced patient benefit than Trikafta and to become a new standard-of-care treatment in CF. It can potentially treat CF patients who have ...

Vertex Pharmaceuticals generated more than $11 billion in product revenue last year thanks to its dominance in cystic fibrosis treatment. Progress in that specialty area and two key drug approvals ...

In the latest development, Google today announced that it would be adding Chirp 3 — its speech-to-text and HD text-to-speech models — to its Vertex AI development platform starting next week.

Spring breakers may be using an underwater scooter under a recall notice through Costco. "We've recently discovered a safety issue in the Sublue Mix underwater scooter batteries manufactured ...

We may receive a commission on purchases made from links. Electric scooters are all the rage these days as people seek the most convenient forms of last mile transportation. Maybe you've tried one ...

The court had heard how the defendant carried out a “dummy run” hours before setting off from his grandmother’s address in Peckham on a scooter to murder Mr Graham, jurors were told.

Vertex has doubled down on cell-based therapies for type 1 diabetes (T1D), buying ViaCyte in a $320 million deal that it says will accelerate development of its own candidate VX-880. The deal has ...